Prevento Pharma

Prevento Pharma is a clinical-stage biopharmaceutical company focused on developing therapies to treat microvascular obstruction and the no-reflow phenomenon in cardiovascular patients. The company's lead product candidate, PRV-002, is a proprietary formulation of adenosine designed for intracoronary administration during Percutaneous Coronary Intervention (PCI). PRV-002 aims to prevent microvascular damage and reduce infarct size in patients suffering from ST-segment elevation myocardial infarction (STEMI). By addressing the limitations of current adenosine treatments, Prevento Pharma seeks to improve long-term clinical outcomes and reduce the incidence of heart failure following a heart attack. The company is led by a management team with extensive experience in cardiovascular drug development and regulatory affairs.